Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Non-Current Assets (2017 - 2025)

Serina Therapeutics (SER) has disclosed Other Non-Current Assets for 9 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $29000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $29000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets hit $29000.0 in Q4 2025 for Serina Therapeutics, up from $24000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $50000.0 in Q1 2021 to a low of $24000.0 in Q3 2025.
  • Historically, Other Non-Current Assets has averaged $47062.5 across 5 years, with a median of $50000.0 in 2021.
  • Biggest YoY gain for Other Non-Current Assets was 0.0% in 2021; the steepest drop was 54.95% in 2021.
  • Year by year, Other Non-Current Assets stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then changed by 0.0% to $50000.0 in 2023, then changed by 0.0% to $50000.0 in 2024, then plummeted by 42.0% to $29000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for SER at $29000.0 in Q4 2025, $24000.0 in Q3 2025, and $50000.0 in Q3 2024.